IVFNCT06502665
Second Ovulation Induction
An observational study of IVF and Infertility, run by Clinique Ovo at 1 site in Canada.
Trial summary
Studies reported various risk factors for inadequate ovulation induction such as body mass index, low ovarian reserve, low baseline FSH and LH, and previous use of contraception or agonist. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- IVF, Infertility
- What is being tested?
- Women having had second ovulation induction after failed oocyte pick-up
- How many people
- 87 participants
- Where
- 1 siteCanada
- Study dates
- 4 Jul 2024to 20 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: Electronic medical record from 2018 to 2023 of patients having undergone an IVF cycle
Who may be able to join
- Participants with no oocytes retrieved in the first ovum pick-up
Who cannot join
- Error in trigger medication or timing by the patient/ medical team
- Major absence of information (primary objective, trigger medication, time interval of trigger and ovum pick-up
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Outcomes From Secondary Ovulation Induction Following Failed Oocyte Pick-up IVF Cycles
Studies reported various risk factors for inadequate ovulation induction such as body mass index, low ovarian reserve, low baseline FSH and LH, and previous use of contraception or agonist.
The flexibility to use human chorionic gonadotropin (hCG) or gonadotropin-releasing hormone agonist (GnRHa) in ovulation induction for antagonist protocol or progestin primed ovarian stimulation (PPOS) is an advantage helping fertility doctors to decrease the risk of ovarian hyperstimulation syndrome. However, luteinizing hormone (LH) levels <15UI/L and progesterone ≤11.13nmol/L eight to twelve hours post GnRHa trigger were highly correlated to failed oocyte pickup (FOP).
Read more
Rescue hCG have been found to increase favorable outcomes in patients with FOP. The presence of false FOP could be due pharmaceutical reasons and human error. Genuine FOP could be due to intrinsic ovarian pathology.
The FOP is defined as the absence of oocytes after ovarian stimulation and follicular aspiration. It is an uncomfortable situation for the patient and medical team to deal with due to the apparent expectations of favorable results.
Ovulation induction could be via GnRHa, HCG, or both in antagonist protocol and PPOS protocol. Long or short agonist protocol could be triggered only via HCG.
- Conditions
- IVF, Infertility
- Being tested
- Women having had second ovulation induction after failed oocyte pick-up
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Women having had second ovulation induction after failed oocyte pick-upOther
IVF success is defined by the number of retrieved oocytes. Identifying women at risk of failed oocyte pick-up at the first oocyte pick-up and optimizing their ovulation induction could enhance outcomes
What is being measured
The primary outcome is the main question the study is designed to answer.
Oocyte pick-up at retrieval
Number of retrieved oocytes after second ovulation induction in patients with FOP
Measured: 36 hours after ovulation triggering
Secondary outcomes (1)
Timing of ovulation triggering
Time interval outcomes between trigger and ovum pickup
Measured: 24 to 36 hours after ovulation triggering
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2024
- Study start4 Jul 2024
- Primary completion30 Jul 2024
- Study completion20 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IVFStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 87 participants (actual)
Sponsor and investigators
- Lead sponsor
- Clinique Ovo
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Simon Phillips, PhD, Principal investigator, Clinique Ovo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06502665
- Sponsor's protocol ID
- 3572
- Status last verified
- Jul 2024
- First submitted
- 9 Jul 2024
- Last updated
- 10 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcomes From Secondary Ovulation Induction Following Failed Oocyte Pick-up IVF Cycles
- ClinicalTrials.gov ID
- NCT06502665
- Acronym / sponsor ID
- 3572
- Conditions
- IVF, Infertility
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 87 participants (actual)
- Lead sponsor
- Clinique OvoIndustry (pharma, biotech, devices)
- Study start
- 4 Jul 2024 (actual)
- Primary completion
- 30 Jul 2024 (actual)
- Study completion
- 20 May 2025 (actual)
- First posted
- 16 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Studies reported various risk factors for inadequate ovulation induction such as body mass index, low ovarian reserve, low baseline FSH and LH, and previous use of contraception or agonist.
The flexibility to use human chorionic gonadotropin (hCG) or gonadotropin-releasing hormone agonist (GnRHa) in ovulation induction for antagonist protocol or progestin primed ovarian stimulation (PPOS) is an advantage helping fertility doctors to decrease the risk of ovarian hyperstimulation syndrome. However, luteinizing hormone (LH) levels <15UI/L and progesterone ≤11.13nmol/L eight to twelve hours post GnRHa trigger were highly correlated to failed oocyte pickup (FOP).
Rescue hCG have been found to increase favorable outcomes in patients with FOP. The presence of false FOP could be due pharmaceutical reasons and human error. Genuine FOP could be due to intrinsic ovarian pathology.
The FOP is defined as the absence of oocytes after ovarian stimulation and follicular aspiration. It is an uncomfortable situation for the patient and medical team to deal with due to the apparent expectations of favorable results.
Ovulation induction could be via GnRHa, HCG, or both in antagonist protocol and PPOS protocol. Long or short agonist protocol could be triggered only via HCG.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Electronic medical record from 2018 to 2023 of patients having undergone an IVF cycle
Key inclusion criteria (1 listed)
- Participants with no oocytes retrieved in the first ovum pick-up
Key exclusion criteria (2 listed)
- Error in trigger medication or timing by the patient/ medical team
- Major absence of information (primary objective, trigger medication, time interval of trigger and ovum pick-up
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Women having had second ovulation induction after failed oocyte pick-upIVF success is defined by the number of retrieved oocytes. Identifying women at risk of failed oocyte pick-up at the first oocyte pick-up and optimizing their ovulation induction could enhance outcomes | Other | – |
Primary outcome
Oocyte pick-up at retrieval
Time frame: 36 hours after ovulation triggering
Number of retrieved oocytes after second ovulation induction in patients with FOP
1 secondary outcome
Timing of ovulation triggering
Time frame: 24 to 36 hours after ovulation triggering
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for IVF
Recruiting
225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women
Infertility (IVF Patients), Infertility Assisted Reproductive Technology
Recruiting
The Effects of Carnitine Supplementation on Oocytes in Women Undergoing IVF Process
Infertility (IVF Patients)
RecruitingPhase 4
Study of G-CSF for DOR in Patients Undergoing IVF
Diminished Ovarian Reserve, IVF
RecruitingObservational study
Machine-Learning Prediction of Pregnancy Outcomes After Assisted Reproductive Treatments
IVF Outcomes, Prediction Models
Recruiting
Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal Responders
ICSI, IVF
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Simon Phillips, PhD principal investigator
Clinique Ovo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of IVF and Infertility, run by Clinique Ovo at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Oocyte pick-up at retrieval (time frame: 36 hours after ovulation triggering). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2025; AzTrials last refreshed its copy on 27 Oct 2026.